Outputs (4)

Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis (2020)
Journal Article
Moreira-Teixeira, L., Tabone, O., Graham, C. M., Singhania, A., Stavropoulos, E., Redford, P. S., …O’Garra, A. (2020). Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis. Nature Immunology, 21(4), 464-476. https://doi.org/10.1038/s41590-020-0610-z

Although mouse infection models have been extensively used to study the host response to Mycobacterium tuberculosis, their validity in revealing determinants of human tuberculosis (TB) resistance and disease progression has been heavily debated. Here... Read More about Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis.

CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth (2019)
Journal Article
Wang, V. M. Y., Ferreira, R. M. M., Almagro, J., Evan, T., Legrave, N., Zaw Thin, M., …Behrens, A. (2019). CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth. Nature Cell Biology, 21, 1425-1435. https://doi.org/10.1038/s41556-019-0407-1

RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
Journal Article
Lionarons, D. A., Hancock, D. C., Rana, S., East, P., Moore, C., Murillo, M. M., …Downward, J. (in press). RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. Cancer Cell, 36(1), 68. https://doi.org/10.1016/j.ccell.2019.05.015

RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S activates PAK, AKT, and a gene expression program initia... Read More about RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Journal Article
Molina-Arcas, M., Moore, C., Rana, S., Van Maldegem, F., Mugarza, E., Romero-Clavijo, P., …Downward, J. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine, https://doi.org/10.1126/scitranslmed.aaw7999

KRAS represents an excellent therapeutic target in lung cancer, the most commonly mutated form of which can now be blocked using KRAS-G12C mutant-specific inhibitory trial drugs. Lung adenocarcinoma cells harboring KRAS mutations have been shown prev... Read More about Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.